PMID- 34630403
OWN - NLM
STAT- MEDLINE
DCOM- 20211227
LR  - 20231102
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - gammadelta T Cells for Leukemia Immunotherapy: New and Expanding Trends.
PG  - 729085
LID - 10.3389/fimmu.2021.729085 [doi]
LID - 729085
AB  - Recently, many discoveries have elucidated the cellular and molecular diversity 
      in the leukemic microenvironment and improved our knowledge regarding their 
      complex nature. This has allowed the development of new therapeutic strategies 
      against leukemia. Advances in biotechnology and the current understanding of T 
      cell-engineering have led to new approaches in this fight, thus improving 
      cell-mediated immune response against cancer. However, most of the investigations 
      focus only on conventional cytotoxic cells, while ignoring the potential of 
      unconventional T cells that until now have been little studied. gammadelta T cells are a 
      unique lymphocyte subpopulation that has an extensive repertoire of tumor sensing 
      and may have new immunotherapeutic applications in a wide range of tumors. The 
      ability to respond regardless of human leukocyte antigen (HLA) expression, the 
      secretion of antitumor mediators and high functional plasticity are hallmarks of 
      gammadelta T cells, and are ones that make them a promising alternative in the field of 
      cell therapy. Despite this situation, in particular cases, the leukemic 
      microenvironment can adopt strategies to circumvent the antitumor response of 
      these lymphocytes, causing their exhaustion or polarization to a tumor-promoting 
      phenotype. Intervening in this crosstalk can improve their capabilities and 
      clinical applications and can make them key components in new therapeutic 
      antileukemic approaches. In this review, we highlight several characteristics of 
      gammadelta T cells and their interactions in leukemia. Furthermore, we explore strategies 
      for maximizing their antitumor functions, aiming to illustrate the findings 
      destined for a better mobilization of gammadelta T cells against the tumor. Finally, we 
      outline our perspectives on their therapeutic applicability and indicate 
      outstanding issues for future basic and clinical leukemia research, in the hope 
      of contributing to the advancement of studies on gammadelta T cells in cancer 
      immunotherapy.
CI  - Copyright (c) 2021 Barros, de Araujo, Magalhaes-Gama, Pereira Ribeiro, Alves Hanna, 
      Tarrago, Malheiro and Costa.
FAU - Barros, Mateus de Souza
AU  - Barros MS
AD  - Diretoria de Ensino e Pesquisa, Fundacao Hospitalar de Hematologia e Hemoterapia 
      do Amazonas (HEMOAM), Manaus, Brazil.
FAU - de Araujo, Nilberto Dias
AU  - de Araujo ND
AD  - Diretoria de Ensino e Pesquisa, Fundacao Hospitalar de Hematologia e Hemoterapia 
      do Amazonas (HEMOAM), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Imunologia Basica e Aplicada, Instituto de Ciencias 
      Biologicas, Universidade Federal do Amazonas (UFAM), Manaus, Brazil.
FAU - Magalhaes-Gama, Fabio
AU  - Magalhaes-Gama F
AD  - Diretoria de Ensino e Pesquisa, Fundacao Hospitalar de Hematologia e Hemoterapia 
      do Amazonas (HEMOAM), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Ciencias da Saude, Instituto Rene Rachou - Fundacao 
      Oswaldo Cruz (FIOCRUZ) Minas, Belo Horizonte, Brazil.
FAU - Pereira Ribeiro, Thais Lohana
AU  - Pereira Ribeiro TL
AD  - Diretoria de Ensino e Pesquisa, Fundacao Hospitalar de Hematologia e Hemoterapia 
      do Amazonas (HEMOAM), Manaus, Brazil.
FAU - Alves Hanna, Fabiola Silva
AU  - Alves Hanna FS
AD  - Diretoria de Ensino e Pesquisa, Fundacao Hospitalar de Hematologia e Hemoterapia 
      do Amazonas (HEMOAM), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Imunologia Basica e Aplicada, Instituto de Ciencias 
      Biologicas, Universidade Federal do Amazonas (UFAM), Manaus, Brazil.
FAU - Tarrago, Andrea Monteiro
AU  - Tarrago AM
AD  - Diretoria de Ensino e Pesquisa, Fundacao Hospitalar de Hematologia e Hemoterapia 
      do Amazonas (HEMOAM), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Ciencias Aplicadas a Hematologia, Universidade do 
      Estado do Amazonas (UEA), Manaus, Brazil.
FAU - Malheiro, Adriana
AU  - Malheiro A
AD  - Diretoria de Ensino e Pesquisa, Fundacao Hospitalar de Hematologia e Hemoterapia 
      do Amazonas (HEMOAM), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Imunologia Basica e Aplicada, Instituto de Ciencias 
      Biologicas, Universidade Federal do Amazonas (UFAM), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Ciencias Aplicadas a Hematologia, Universidade do 
      Estado do Amazonas (UEA), Manaus, Brazil.
FAU - Costa, Allyson Guimaraes
AU  - Costa AG
AD  - Diretoria de Ensino e Pesquisa, Fundacao Hospitalar de Hematologia e Hemoterapia 
      do Amazonas (HEMOAM), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Imunologia Basica e Aplicada, Instituto de Ciencias 
      Biologicas, Universidade Federal do Amazonas (UFAM), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Ciencias Aplicadas a Hematologia, Universidade do 
      Estado do Amazonas (UEA), Manaus, Brazil.
AD  - Programa de Pos-Graduacao em Medicina Tropical, UEA, Manaus, Brazil.
AD  - Instituto de Pesquisa Clinica Carlos Borborema, Fundacao de Medicina Tropical 
      Doutor Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil.
AD  - Escola de Enfermagem de Manaus, UFAM, Manaus, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210922
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use
MH  - *Immunotherapy, Adoptive/adverse effects
MH  - Intraepithelial Lymphocytes/*drug effects/immunology/metabolism/*transplantation
MH  - Leukemia/genetics/immunology/metabolism/*therapy
MH  - Lymphocyte Activation/drug effects
MH  - Lymphocytes, Tumor-Infiltrating/immunology/metabolism
MH  - Phenotype
MH  - Receptors, Chimeric Antigen/genetics/immunology/metabolism
MH  - Signal Transduction
MH  - Tumor Microenvironment
PMC - PMC8493128
OTO - NOTNLM
OT  - cell transplantation
OT  - clinical trials
OT  - gamma-delta T cells
OT  - leukemic microenvironment
OT  - off-the-shelf cell therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/12 06:00
MHDA- 2021/12/28 06:00
PMCR- 2021/01/01
CRDT- 2021/10/11 05:55
PHST- 2021/06/22 00:00 [received]
PHST- 2021/08/30 00:00 [accepted]
PHST- 2021/10/11 05:55 [entrez]
PHST- 2021/10/12 06:00 [pubmed]
PHST- 2021/12/28 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.729085 [doi]
PST - epublish
SO  - Front Immunol. 2021 Sep 22;12:729085. doi: 10.3389/fimmu.2021.729085. eCollection 
      2021.